title: Safety and immunogenicity of the 23-valent pneumococcal polysaccharide vaccine at 12 months of age, following one, two, or three doses of the 7-valent pneumococcal conjugate vaccine in infancy.
abstract: Fijian infants aged 6 weeks were stratified by ethnicity and randomized to receive 0, 1, 2, or 3 PCV-7 doses with or without the 23-valent pneumococcal polysaccharide vaccine (PPV-23) at 12 months. Strong booster effects for all 7 PCV-7 serotypes were elicited, and for 4/7 serotypes these responses were highest in the single PCV-7 group. There were fourfold rises in GMC for all non-PCV-7 serotypes. By 17 months the PPV-23 group still had significantly higher GMC (each p<0.001) for all serotypes. The PPV-23 was well tolerated and induced excellent responses for all serotypes which were greatest in the single PCV-7 group.
authors.affiliation: Centre for International Child Health, Department of Paediatrics, University of Melbourne, Royal Children's Hospital, Melbourne, Australia. fmruss@unimelb.edu.au
authors.forename: F M
authors.initials: FM
authors.lastname: Russell
authors.forename: P V
authors.initials: PV
authors.lastname: Licciardi
authors.forename: A
authors.initials: A
authors.lastname: Balloch
authors.forename: V
authors.initials: V
authors.lastname: Biaukula
authors.forename: L
authors.initials: L
authors.lastname: Tikoduadua
authors.forename: J R
authors.initials: JR
authors.lastname: Carapetis
authors.forename: J
authors.initials: J
authors.lastname: Nelson
authors.forename: A W J
authors.initials: AW
authors.lastname: Jenney
authors.forename: L
authors.initials: L
authors.lastname: Waqatakirewa
authors.forename: S
authors.initials: S
authors.lastname: Colquhoun
authors.forename: Y B
authors.initials: YB
authors.lastname: Cheung
authors.forename: M L K
authors.initials: ML
authors.lastname: Tang
authors.forename: E K
authors.initials: EK
authors.lastname: Mulholland
mesh_terms: D000907:Antibodies, Bacterial / Q000097:blood*; D002675:Child, Preschool; D000069443:Heptavalent Pneumococcal Conjugate Vaccine; D006801:Humans; D007115:Immunization Schedule; D007117:Immunization, Secondary / Q000379:methods*; D007074:Immunoglobulin G / Q000097:blood; D007223:Infant; D022242:Pneumococcal Vaccines / Q000009:adverse effects* / Q000276:immunology*
chemical_list: C414006:23-valent pneumococcal capsular polysaccharide vaccine; D000907:Antibodies, Bacterial; D000069443:Heptavalent Pneumococcal Conjugate Vaccine; D007074:Immunoglobulin G; D022242:Pneumococcal Vaccines